Close Menu

NEW YORK (GenomeWeb) — Promega announced today that Japan's Ministry of Health, Labour, and Welfare has approved a companion diagnostic for Merck's cancer immunotherapy Keytruda (pembrolizumab) based on its microsatellite instability (MSI) technology.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.


This webinar will discuss how the Molecular Pathology Laboratory at the University of Oklahoma (OUMP) is using a new quality improvement model to support molecular testing of oncology patients.